Stool DNA testing has emerged as an innovative, non-invasive method to diagnose colorectal cancer at an early stage. It relies on the detection of specific DNA markers in stool samples, which can indicate the presence of colorectal cancer or precancerous lesions. One pioneering solution in this area is IColocomf, developed by the Wuhan Ammunition Life-tech Co.,Ltd (WALT), a leading Chinese manufacturer and supplier specializing in non-invasive detection products for high-incidence malignant tumors.
Understanding Stool DNA Testing
Stool DNA testing, such as the IColocomf, identifies DNA alterations in cells that are shed from the lining of the colon into the stool. These alterations could be indicative of colorectal cancer or precancerous polyps. The test is non-invasive, making it a convenient, fast, and precise method for early colorectal cancer screening.
The IColocomf Advantage
IColocomf, a product of WALT, is a stool DNA Methylation detection kit for Colorectal Cancer that detects the methylated SDC2 and TFPI2 genes in intestinal exfoliated cells from human stool samples. It employs a unique atomic signal capture technique (AS-CAP) that enhances sensitivity for methylation specific qPCR. The results are available within 4.5 hours since the sample processing.
The IColocomf kit is highly efficient, odorless, accurate and cost-effective. It keeps the DNA stable for more than 15 days, making it a more convenient and reasonable alternative to colonoscopy.
Who Should Consider Stool DNA Testing?
Stool DNA testing can be an essential preventive measure for individuals over 40, those with a history of colorectal cancer or related symptoms, and individuals with a history of colorectal disease, unexplained anemia, or chronic appendicitis.
WALT: Your Trusted Partner
At WALT, we are committed to saving lives by providing cutting-edge diagnosis products for several high-incidence malignant tumors. Apart from IColocomf, we have a range of detection products like IColohunter, IEsohunter, IHepcomf, ICervsure, and IUterusure.
We have successfully established ourselves as a trusted B2B exporter, manufacturer, and supplier in the medical field. With 3 branch offices in China, including a headquarter in Wuhan City, and an office in Zhengzhou, we are well-equipped to meet your business needs.
Our commitment to quality is reflected in our ISO13485 certification and successful on-site audits from clients. We combine cutting-edge epigenetics, bioinformatics, clinical big data, and artificial intelligence analysis to create a new generation of tumor screening and detection technology platform.
To learn more about our work and the importance of early detection, read Understanding Liver Cancer Tests and How to Perform Them Effectively.
In conclusion, stool DNA testing, such as the IColocomf from WALT, can provide an efficient, non-invasive, and cost-effective method for early colorectal cancer detection. By integrating these tests into routine check-ups, we can significantly improve the prognosis and survival rates for individuals diagnosed with this disease.